Correlative Studies in Protocol E4412, which Studied Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma, in Collaboration with CIMAC-CIDC
Getting access
No access information recorded yet.
About this database
| Last updated | 2026-08-25 |
|---|